Abstract
Respiratory diseases including chronic-obstructive-pulmonary-disease (COPD) are globally increasing, with COPD predicted to become the third leading cause of global mortality by 2020. COPD is a heterogeneous disease with COPD-patients displaying different phenotypes as a result of a complex interaction between various genetic, environmental and life-style factors. In recent years, several investigations have been performed to better define such interactions, but the identification of the resulting phenotypes is still somewhat difficult, and may lead to inadequate assessment and management of COPD (usually based solely on the severity of airflow limitation parameter FEV1). In this new scenario, the management of COPD has been driven towards an integrative and holistic approach. The degree of complexity requires analyses based on large datasets (also including advanced functional genomic assays) and novel computational biology approaches (essential to extract information relevant for the clinical decision process and for the development of new drugs). Therefore, according to the emerging “systems/network medicine”, COPD should be re.-evaluated considering multiple network(s) perturbations such as genetic and environmental changes. Systems Medicine (SM) platforms, in which patients are extensively characterized, offer a basis for a more targeted clinical approach, which is predictive, preventive, personalized and participatory (“P4-medicine”). It clearly emerges that in the next future, new opportunities will become available for clinical research on rare COPD patterns and for the identification of new biomarkers of comorbidity, severity, and progression. Herein, we overview the literature discussing the opportunity coming from the adoption of SMapproaches in COPD management, focusing on proteomics and metabolomics, and emphasizing the identification of disease sub-clusters, to improve the development of more effective therapies.
Keywords: COPD, Comorbidities, Metabolomics, Systems Medicine, Proteomics, P4 Medicine.
Current Medicinal Chemistry
Title:Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Volume: 22 Issue: 32
Author(s): Filippo Lococo, Alfredo Cesario, Alessandra Del Bufalo, Alessia Ciarrocchi, Giulia Prinzi, Marco Mina, Stefano Bonassi and Patrizia Russo
Affiliation:
Keywords: COPD, Comorbidities, Metabolomics, Systems Medicine, Proteomics, P4 Medicine.
Abstract: Respiratory diseases including chronic-obstructive-pulmonary-disease (COPD) are globally increasing, with COPD predicted to become the third leading cause of global mortality by 2020. COPD is a heterogeneous disease with COPD-patients displaying different phenotypes as a result of a complex interaction between various genetic, environmental and life-style factors. In recent years, several investigations have been performed to better define such interactions, but the identification of the resulting phenotypes is still somewhat difficult, and may lead to inadequate assessment and management of COPD (usually based solely on the severity of airflow limitation parameter FEV1). In this new scenario, the management of COPD has been driven towards an integrative and holistic approach. The degree of complexity requires analyses based on large datasets (also including advanced functional genomic assays) and novel computational biology approaches (essential to extract information relevant for the clinical decision process and for the development of new drugs). Therefore, according to the emerging “systems/network medicine”, COPD should be re.-evaluated considering multiple network(s) perturbations such as genetic and environmental changes. Systems Medicine (SM) platforms, in which patients are extensively characterized, offer a basis for a more targeted clinical approach, which is predictive, preventive, personalized and participatory (“P4-medicine”). It clearly emerges that in the next future, new opportunities will become available for clinical research on rare COPD patterns and for the identification of new biomarkers of comorbidity, severity, and progression. Herein, we overview the literature discussing the opportunity coming from the adoption of SMapproaches in COPD management, focusing on proteomics and metabolomics, and emphasizing the identification of disease sub-clusters, to improve the development of more effective therapies.
Export Options
About this article
Cite this article as:
Lococo Filippo, Cesario Alfredo, Bufalo Del Alessandra, Ciarrocchi Alessia, Prinzi Giulia, Mina Marco, Bonassi Stefano and Russo Patrizia, Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach, Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666150904113032
DOI https://dx.doi.org/10.2174/0929867322666150904113032 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prostacyclin Synthase Gene: Genetic Polymorphisms and Prevention of Some Cardiovascular Diseases
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Coronary Atherosclerosis The Implications of Being a Woman
Current Hypertension Reviews Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation From Early Origins. When and Why does Asthma Develop?
Current Pediatric Reviews Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents